• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Thermo Fisher Scientific Invests to Enhance U.S. Innovation and Support Customers' Manufacturing

    4/24/25 8:00:00 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials
    Get the next $TMO alert in real time by email

    Investment demonstrates confidence in America's commitment to science and innovation

    Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, will invest an additional $2 billion in the United States over the next four years, strengthening American innovation, manufacturing and economic competitiveness across the life sciences sector.

    As one of the largest manufacturers of medicines in the world, Thermo Fisher enables biopharma companies to develop and produce their medicines in America. These additional investments to the company's American manufacturing capacity support a resilient U.S. healthcare supply chain and will have a strong multiplier effect across the American economy.

    The $2 billion investment over the next four years includes:

    • $1.5 billion in capital expenditures to enhance and expand U.S. manufacturing operations
    • Complemented by $500 million in R&D focused on high-impact innovation

    "Thermo Fisher's commitment to U.S. manufacturing reflects our confidence that America will continue to lead the world in science and innovation. Thermo Fisher is proud to serve as a growth engine for the American economy," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. "By expanding our U.S. operations, we ensure that life-saving medicines and therapies will continue to be developed and produced in America for decades to come."

    This investment builds on Thermo Fisher's industry-leading foundation in U.S. manufacturing and innovation. The company has 64 U.S. manufacturing operations, located in 37 states, making analytical instruments, specialty diagnostics and life sciences solutions, as well as providing contract development and manufacturing services for pharmaceutical innovators.

    Since 2017, Thermo Fisher has more than doubled in size—from $21 billion in revenue and 28,000 U.S. employees to $43 billion in revenue and more than 50,000 U.S. employees today. The company also invests $1 billion annually in R&D in the U.S. Over the next four years, the company will continue to expand its impact in the U.S. by creating high-paying jobs, adding manufacturing and lab services capacity, and investing in research and development.

    About Thermo Fisher Scientific

    Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

    Safe Harbor Statement

    The following constitutes a "Safe Harbor" statement under the Private Securities Litigation Reform

    Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers' capital spending policies and government funding policies; the effect of economic and political conditions and exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; any natural disaster, public health crisis or other catastrophic event; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent or pending acquisitions, may not materialize as expected. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in our most recent annual report on Form 10-K, which is on file with the SEC and available in the "Investors" section of our website under the heading "SEC Filings." While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250424389005/en/

    Media Contact Information:

    Sandy Pound

    Phone: 781-622-1223

    E-mail: [email protected]

    Website: www.thermofisher.com

    Investor Contact Information:

    Rafael Tejada

    Phone: 781-622-1356

    E-mail: [email protected]

    Get the next $TMO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $TMO

    DatePrice TargetRatingAnalyst
    7/24/2025$510.00Buy → Hold
    HSBC Securities
    7/11/2025$590.00Sector Perform → Sector Outperform
    Scotiabank
    7/9/2025$460.00Buy → Neutral
    UBS
    1/10/2025$630.00Mkt Perform → Outperform
    Bernstein
    12/23/2024Sector Perform
    Scotiabank
    10/14/2024Buy
    Redburn Atlantic
    10/1/2024$680.00Overweight
    Stephens
    8/28/2024$670.00Overweight
    Wells Fargo
    More analyst ratings

    $TMO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Thermo Fisher Scientific's Chief Financial Officer, Stephen Williamson, to Retire in Early 2026

      Jim Meyer to Become Chief Financial Officer, Effective March 1, 2026 Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that Stephen Williamson, senior vice president and chief financial officer (CFO), has decided to retire from the company, effective March 31, 2026. The company's board of directors has approved the appointment of Jim Meyer, currently vice president of financial operations, to succeed Williamson as CFO, effective March 1, 2026. Williamson, age 58, has led Thermo Fisher's global finance organization as CFO since 2015. He joined the company in 2001 as Vice President, European Financial Operations. To ensure a seamless transition

      7/23/25 9:00:00 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Thermo Fisher Scientific Reports Second Quarter 2025 Results

      Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 28, 2025. Second Quarter Highlights Second quarter revenue grew 3% to $10.85 billion. Second quarter GAAP diluted earnings per share (EPS) grew 6% to $4.28. Second quarter adjusted EPS was $5.36. Delivered excellent operational performance in the quarter, reflecting active management of our company in the macroenvironment demonstrating the strength of our proven growth strategy and the power of the PPI Business System. Advanced our proven growth strategy, launching a range of high-impact innovation, strengthening our industr

      7/23/25 6:00:00 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Thermo Fisher Scientific and Sanofi Expand Strategic Partnership to Enable Additional U.S. Drug Product Manufacturing

      Thermo Fisher to Acquire Sanofi's Steriles Manufacturing Site in Ridgefield, New Jersey to Produce Critical Medicines for Sanofi Enables Additional U.S. Manufacturing Capacity to Serve Increased Demand for Pharma/Biotech Customers Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced an expansion of their strategic partnership with Sanofi to enable additional U.S. drug product manufacturing. The terms of the deal were not disclosed. Under the agreement, Thermo Fisher will acquire Sanofi's steriles manufacturing site in Ridgefield, New Jersey and will continue to manufacture a portfolio of therapies for Sanofi. In addition, Thermo Fisher will ex

      7/16/25 8:00:00 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials

    $TMO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Chai Nelson sold $8,449 worth of shares (16 units at $528.09) and bought $11,038 worth of shares (20 units at $551.90), increasing direct ownership by 0.03% to 14,252 units (SEC Form 4)

      4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

      2/21/25 4:19:32 PM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Boxer Michael A bought $2,105 worth of shares (4 units at $526.15), increasing direct ownership by 0.03% to 13,101 units (SEC Form 4)

      4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

      10/6/23 4:23:51 PM ET
      $TMO
      Industrial Machinery/Components
      Industrials

    $TMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Weisler Dion J

      4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

      7/1/25 4:23:49 PM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • SEC Form 4 filed by Director Sperling Scott M

      4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

      7/1/25 4:21:18 PM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • SEC Form 4 filed by Director Keith R. Alexandra

      4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

      7/1/25 4:18:48 PM ET
      $TMO
      Industrial Machinery/Components
      Industrials

    $TMO
    SEC Filings

    See more
    • Thermo Fisher Scientific Inc filed SEC Form 8-K: Leadership Update

      8-K - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)

      7/23/25 4:16:06 PM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Thermo Fisher Scientific Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)

      7/23/25 6:03:44 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • SEC Form 11-K filed by Thermo Fisher Scientific Inc

      11-K - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)

      6/17/25 2:30:55 PM ET
      $TMO
      Industrial Machinery/Components
      Industrials

    $TMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Thermo Fisher downgraded by HSBC Securities with a new price target

      HSBC Securities downgraded Thermo Fisher from Buy to Hold and set a new price target of $510.00

      7/24/25 9:29:26 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Thermo Fisher upgraded by Scotiabank with a new price target

      Scotiabank upgraded Thermo Fisher from Sector Perform to Sector Outperform and set a new price target of $590.00

      7/11/25 7:57:15 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Thermo Fisher downgraded by UBS with a new price target

      UBS downgraded Thermo Fisher from Buy to Neutral and set a new price target of $460.00

      7/9/25 8:19:41 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials

    $TMO
    Financials

    Live finance-specific insights

    See more
    • Thermo Fisher Scientific Reports Second Quarter 2025 Results

      Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 28, 2025. Second Quarter Highlights Second quarter revenue grew 3% to $10.85 billion. Second quarter GAAP diluted earnings per share (EPS) grew 6% to $4.28. Second quarter adjusted EPS was $5.36. Delivered excellent operational performance in the quarter, reflecting active management of our company in the macroenvironment demonstrating the strength of our proven growth strategy and the power of the PPI Business System. Advanced our proven growth strategy, launching a range of high-impact innovation, strengthening our industr

      7/23/25 6:00:00 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Thermo Fisher Scientific Declares Quarterly Dividend

      Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.43 per common share, payable on October 15, 2025, to shareholders of record as of September 15, 2025. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the

      7/10/25 4:15:00 PM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, July 23, 2025

      Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2025 before the market opens on Wednesday, July 23, 2025, and will hold a conference call on the same day at 8:30 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The access code is 523661. You may also listen to the call live on the "Investors" section of our website, www.thermofisher.com. The earnings press release and related information can also be found in that section of our website under t

      7/1/25 8:00:00 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials

    $TMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Thermo Fisher Scientific Inc (Amendment)

      SC 13G/A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)

      2/9/23 11:35:13 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13G/A filed

      SC 13G/A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)

      2/10/21 11:57:23 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials

    $TMO
    Leadership Updates

    Live Leadership Updates

    See more
    • Thermo Fisher Scientific's Chief Financial Officer, Stephen Williamson, to Retire in Early 2026

      Jim Meyer to Become Chief Financial Officer, Effective March 1, 2026 Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that Stephen Williamson, senior vice president and chief financial officer (CFO), has decided to retire from the company, effective March 31, 2026. The company's board of directors has approved the appointment of Jim Meyer, currently vice president of financial operations, to succeed Williamson as CFO, effective March 1, 2026. Williamson, age 58, has led Thermo Fisher's global finance organization as CFO since 2015. He joined the company in 2001 as Vice President, European Financial Operations. To ensure a seamless transition

      7/23/25 9:00:00 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • 908 Devices Appoints Christopher D. Brown to its Board of Directors

      908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (NASDAQ:RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately. Dr. Brown co-founded 908 Devices and served as the company's Chief Technology Officer & Vice President of Research & Development from February 2012 to March 2023, and as its Chief Product Officer from March 2023 until March 2025 when Repligen purchased the company's bioprocessing portfolio. Prior to 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ:AAPL) lead

      6/16/25 8:00:00 AM ET
      $AAPL
      $MASS
      $RGEN
      $TMO
      Computer Manufacturing
      Technology
      Industrial Machinery/Components
      Industrials
    • GeminiBio Appoints Mike Stella to Board

      Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

      2/18/25 9:00:00 AM ET
      $AMGN
      $GSK
      $JNJ
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Industrial Machinery/Components